GetTopicDetailResponse(id=a1c22538163, topicName=代償期肝硬化, introduction=代償期肝硬化, content=null, image=null, comments=0, allHits=343, url=https://h5.medsci.cn/topic?id=25381, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=78303, tagList=[TagDto(tagId=78303, tagName=代償期肝硬化)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2265434, encodeId=278422654346f, content=<a href='/topic/show?id=a1c22538163' target=_blank style='color:#2F92EE;'>#代償期肝硬化#</a> <a href='/topic/show?id=7333112311d1' target=_blank style='color:#2F92EE;'>#MASH#</a>, objectTitle=N Engl J Med：肝臟“石化”有救了？Efruxifermin最新臨床試驗：36周遇挫，96周現(xiàn)轉機！, objectType=article, longId=875862, objectId=cda48e5862d6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736847778037_8538692.png, objectUrl=/article/show_article.do?id=cda48e5862d6, replyNumber=0, likeNumber=35, createdTime=2025-05-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cda48e5862d6, moduleTitle=N Engl J Med：肝臟“石化”有救了？Efruxifermin最新臨床試驗：36周遇挫，96周現(xiàn)轉機！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cda48e5862d6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2265199, encodeId=16782265199c9, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝細胞癌#</a> <a href='/topic/show?id=a1c22538163' target=_blank style='color:#2F92EE;'>#代償期肝硬化#</a> <a href='/topic/show?id=107112684903' target=_blank style='color:#2F92EE;'>#EASL 2025#</a>, objectTitle=EASL 2025 | 臨床顯著性門脈高壓對代償期肝硬化合并HCC患者預后的影響：HIPERIA研究, objectType=article, longId=877544, objectId=b4188e7544ed, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736847778037_8538692.png, objectUrl=/article/show_article.do?id=b4188e7544ed, replyNumber=0, likeNumber=35, createdTime=2025-05-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b4188e7544ed, moduleTitle=EASL 2025 | 臨床顯著性門脈高壓對代償期肝硬化合并HCC患者預后的影響：HIPERIA研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b4188e7544ed)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2255525, encodeId=cd17225552595, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=a1c22538163' target=_blank style='color:#2F92EE;'>#代償期肝硬化#</a>, objectTitle=【期刊導讀】核苷序貫/聯(lián)合PEG IFNα-2b治療可顯著提高慢乙肝或代償期肝硬化患者的HBsAg清除率, objectType=article, longId=865241, objectId=704686524190, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250122/1737543636981_8538692.jpg, objectUrl=/article/show_article.do?id=704686524190, replyNumber=0, likeNumber=36, createdTime=2025-03-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=704686524190, moduleTitle=【期刊導讀】核苷序貫/聯(lián)合PEG IFNα-2b治療可顯著提高慢乙肝或代償期肝硬化患者的HBsAg清除率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=704686524190)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯話題小助手
2020-05-29
